A5063617604- Glioma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Meningioma and schwannoma management
- Radiopharmaceutical Chemistry and Applications
- Dementia and Cognitive Impairment Research
- Amino Acid Enzymes and Metabolism
- Cancer Immunotherapy and Biomarkers
- Migraine and Headache Studies
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Glaucoma and retinal disorders
- Cholinesterase and Neurodegenerative Diseases
- Memory and Neural Mechanisms
- Neuroinflammation and Neurodegeneration Mechanisms
- Tryptophan and brain disorders
- Neuroscience and Neuropharmacology Research
- Brain Metastases and Treatment
- Alzheimer's disease research and treatments
- Vestibular and auditory disorders
University Hospital Cologne
2018-2025
University of Cologne
2018-2025
Witten/Herdecke University
2020
Life & Brain (Germany)
2016
University of Bonn
2016
The glioblastoma, a malignant human brain tumor, is known for its devastating intracranial progress and dismal prognosis. Whereas treatment research are most prominently focused on the primary tumor lesion, in recent years evidence has accumulated that points to rare occurrence of extracranial glioblastoma metastases. We here present case female patient with who was detected harbor multiple metastases bones, lung, pleura, liver, mesentery, subcutaneous soft tissue. Pathogenetically, these...
The goal of this study was to compare the value contrast-enhanced MRI and O-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine (<sup>18</sup>F-FET) PET for response assessment in glioma patients after adjuvant temozolomide chemotherapy (TMZ). <b>Methods:</b> After biopsy or resection completion radiotherapy with concomitant TMZ, 41 newly diagnosed histomolecularly characterized (glioblastoma, 90%; age range, 20–79 y) were subsequently treated TMZ. MR <sup>18</sup>F-FET imaging performed at baseline...
O-(2-[18F]fluoroethyl)-L-tyrosine (FET) is a widely used amino acid tracer for positron emission tomography (PET) imaging of brain tumours. This retrospective study and survey aimed to analyse our extensive database regarding the development FET PET investigations, indications, referring physicians' rating concerning role in clinical decision-making process. Between 2006 2019, we performed 6534 scans on 3928 different patients against backdrop growing demand PET. In indications use were as...
Integrated histomolecular diagnostics of gliomas according to the World Health Organization (WHO) classification 2016 has refined diagnostic accuracy and prediction prognosis. This study aimed at exploring prognostic value dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed, histomolecularly classified astrocytic WHO grades III or IV.Before initiation treatment, FET imaging was performed patients with diagnosed glioblastoma (GBM) anaplastic astrocytoma (AA). Static...
One of the most common clinical indications for amino acid PET using tracer <i>O</i>-(2-[<sup>18</sup>F]-fluoroethyl)-l-tyrosine (<sup>18</sup>F-FET) is differentiation tumor relapse from treatment-related changes in patients with gliomas. A subset may present an uptake <sup>18</sup>F-FET close to recommended threshold values. The goal this study was investigate frequency borderline cases and role quantitative parameters situation. <b>Methods:</b> We retrospectively identified 439 pretreated...
Abstract Purpose PET using the radiolabeled amino acid O -(2-[ 18 F]-fluoroethyl)-L-tyrosine ([ F]FET) has considerable clinical value for follow-up evaluation of central nervous system tumors in children and adolescents. As medical procedures must be justified socio-economically, we determined cost-effectiveness [ F]FET identification treatment-related changes. Methods We analyzed data from two different studies that assessed FET to differentiate between brain spinal tumor relapse changes...
In light of increasing health-care costs, higher medical expenses should be justified socioeconomically. Therefore, we calculated the effectiveness and cost PET using radiolabeled amino acid O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) compared with conventional MRI for early identification responders to adjuvant temozolomide chemotherapy. A recently published study in isocitrate dehydrogenase wild-type glioma patients suggested that 18F-FET parameter changes predicted a significantly longer...
Abstract In glioma patients, complete resection of the contrast-enhancing portion is associated with improved survival, which, however, cannot be achieved in a considerable number patients. Here, we evaluated prognostic value O -(2-[ 18 F]-fluoroethyl)-L-tyrosine (FET) PET not completely resectable patients minimal or absent contrast enhancement before temozolomide chemoradiation. Dynamic FET scans were performed newly diagnosed partially resected (n = 8) biopsied 10) IDH-wildtype astrocytic...
PET using the radiolabeled amino acid <i>O</i>-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine (<sup>18</sup>F-FET) has been shown to be of value for treatment monitoring in patients with brain metastases after multimodal therapy, especially clinical situations equivocal MRI findings. As medical procedures must justified socioeconomically, we determined effectiveness and cost-effectiveness <sup>18</sup>F-FET including checkpoint inhibitors, targeted therapies, radiotherapy, combinations thereof...
Ziel/Aim Integrated histomolecular diagnostics of gliomas according to the World Health Organization (WHO) classification 2016 has refined diagnostic accuracy and prediction prognosis. This study aimed at exploring prognostic value dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed, histomolecularly classified astrocytic WHO grades III or IV.
Abstract Background Anti‐amyloid beta (Aβ) immunotherapies have recently evolved as promising treatment options in patients with early symptomatic Alzheimer’s disease (AD). Meanwhile, accurate patient selection for these treatments might be challenging mirrored by strict criteria of the hitherto published clinical trials. Based on a real‐world tertiary care sample post‐mortem validated cases, we aimed to identify matching and their proportion showing AD pathology. Method This study is based...
The goal of this prospective study was to compare the value conventional MRI and O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET for response assessment in patients with malignant glioma treated first-line adjuvant temozolomide chemotherapy (TMZ). After biopsy/resection completion radiotherapy concomitant temozolomide, 34 (glioblastoma, n=31; IDH-wildtype anaplastic astrocytoma, n=2; H3K27-mutated midline glioma, n=1) (age range, 20–66 years) were subsequently TMZ (5/28). FET-PET scans performed...
The pupillary light reflex (PLR) is a key component of the physical examination as it reliably tests functional integrity neuromuscular loop between pupil and midbrain. Unlike traditional manual testing PLR with penlight that frequently leads to incorrect interpretation due its subjectivity, specialized “pupillometer” tool allows objective trending data. We performed quantitative unilateral pupillometry several times in 53 healthy subjects (aged 21-74) different background illumination...
Abstract Background Prediction of the course cognitive function is central importance in care patients with dementia Alzheimer type (DAT) for individual management, counseling and treatment. Baseline clinical examination testing are decisive classification stage, but their predictive value to foresee future disease critical. This project aims examine relationship baseline stage Alzheimer’s neuropathological changes (ADNC) at autopsy during disease. Method study based on longitudinal data...
Abstract BACKGROUND A complete resection of high-grade gliomas (HGG) is associated with improved survival, which, however, cannot be achieved in a considerable number patients. We here evaluated the prognostic value serial O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET patients newly diagnosed, non-resectable astrocytic HGG undergoing chemoradiation temozolomide. MATERIAL AND METHODS Serial dynamic FET scans were performed 18 diagnosed molecularly defined, at baseline and after (8±3 weeks)....
Abstract BACKGROUND Following neurooncological treatment of brain tumors, neurooncologists are frequently confronted with equivocal MRI findings (e.g., treatment-related changes, nonmeasurable (speckled) contrast-enhancing lesions, increase T2/FLAIR signal alterations, pseudoresponse). Especially in Europe, amino acid PET is increasingly being integrated into multidisciplinary tumor boards (MNTB) to overcome these diagnostic uncertainties as well improve patient management. We here evaluated...
Abstract Background Acetylcholinesterase inhibitors (AchE‐I) and memantine are licensed recommended for the treatment of dementia Alzheimer type (DAT). Between 10 20 % patients with DAT, however, do not have Alzheimer’s disease (AD) pathology. It remains unclear, if these also benefit from treatment. This project aims to examine association AchE‐I use cognitive function in DAT without evidence AD pathology at autopsy. Method study is based on The National Alzheimer‘s Coordinating...
Abstract BACKGROUND In light of increasing healthcare costs, higher medical expenses should be justified socio-economically. Therefore, we calculated the effectiveness and cost-effectiveness PET using radiolabeled amino acid O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) compared to conventional MRI for early identification responders adjuvant temozolomide chemotherapy. A recent study in IDH-wildtype glioma patients suggested that after two cycles, FET-PET parameter changes predicted a...
Abstract Purpose: In glioma patients, complete resection of the contrast-enhancing portion is associated with improved survival, which, however, cannot be achieved in a considerable number patients. Here, we evaluated prognostic value O -(2-[ 18 F]-fluoroethyl)-L-tyrosine (FET) PET not completely resectable patients minimal or absent contrast enhancement before temozolomide chemoradiation. Methods: Dynamic FET scans were performed newly diagnosed partially resected (n=8) biopsied (n=10)...